We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00545896
Recruitment Status : Completed
First Posted : October 17, 2007
Last Update Posted : July 18, 2011
Information provided by:

October 16, 2007
October 17, 2007
July 18, 2011
September 2003
June 2010   (Final data collection date for primary outcome measure)
All cause mortality [ Time Frame: 30 days after last ESWT session ]
Same as current
Complete list of historical versions of study NCT00545896 on ClinicalTrials.gov Archive Site
Rate of complete wound closure and number of ESWT sessions needed. Rate of nonhealing wounds and number of ESWT sessions until drop out/ reasons for drop out. [ Time Frame: 30 days after last ESWT session or drop out date. ]
Same as current
Not Provided
Not Provided
Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds
Safety and Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Chronic Soft Tissue Wounds

Chronic soft tissue wounds represent a difficult problem for patients and doctors as well. Chronic wounds can be caused by internal and dermatological diseases like venous ulcers as a consequence of venous insufficiency, arterial ulcers as a consequence of peripheral occlusive vascular disease, the diabetic foot stemming from diabetes and other pathologies. A different reason for chronic wounds could be prior traumatic injuries (war wounds, traffic accidents)not showing a tendency to heal after surgical repair.

The primary goal in the treatment of chronic soft tissue wounds is to obtain wound closure. Usually necrotic tissue is debrided, i.e. surgically removed, to assess the full extent of the damage, to detect underlying abscesses or other pathologies causing the non-healing of the wound. Wet - to - wet dressings are primarily applied to induce a healing process. As second line attempts to obtain closure special dressings like semipermeable films, gels, hydrocolloids and calcium alginates are applied. These expensive dressings are associated with extended time periods of conservative treatment until closure can be observed.

A third line after failure of nonoperative treatment is the application of skin graft. This involves the operative and anesthesiological risk for an already health wise compromised patient with little to no physiological reserve. One should not forget that the majority of patients presenting at outpatient clinics with chronic soft tissue wounds are the elderly with/without disabling comorbidities.

The use of extracorporeal shockwaves (ESW) for clinical applications was introduced in central Europe more than two decades ago. Extracorporeal shockwave therapy (ESWT)is used in the fields of urology, orthopedic surgery, trauma surgery. ESW are associated with the induction of neovascularisation and with mechanical stimuli causing proliferation of a large number of cells including osteoblasts (Martini L., J Trauma 2006). The exact effects of ESW on human cells are currently studied in several centers worldwide. The application of ESWT in the above mentioned fields of medicine proved safe, reliable and almost complication-free.

Our center's experience with ESWT in trauma surgery (Schaden W., Clin. Orthop 2001)and the observation that not only the traumatic condition (fracture non-union, etc.), but also the surrounding tissue showed favorable tissue healing after ESWT, leads to our hypothesis that ESWT might be beneficial for the much larger number of chronic soft tissue wounds. The investigators anticipate to induce complete wound healing in a number of defined clinical/pathological conditions by ESWT. At the same time efficacy and safety of ESWT will be investigated.

Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Chronic Nonhealing Wounds
Procedure: Extracorporeal shockwave therapy
Extracorporeal application of shockwaves on the surface of chronic wounds.
Not Provided
Wolff KS, Wibmer A, Pusch M, Prusa AM, Pretterklieber M, Teufelsbauer H, Schaden W. The influence of comorbidities and etiologies on the success of extracorporeal shock wave therapy for chronic soft tissue wounds: midterm results. Ultrasound Med Biol. 2011 Jul;37(7):1111-9. doi: 10.1016/j.ultrasmedbio.2011.04.007. Epub 2011 Jun 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of a chronic soft tissue wound persisting for longer than one month.
  • Cause of chronic wound irrelevant except circumferential second degree burn wounds of upper/lower extremity.
  • Capable of wound care at home or home nursing available.
  • Patients older than 18 years.
  • The patient is willing, able to read, understand and willing to give informed consent to the study procedure.
  • Female patients will not be pregnant.
  • The patient will agree to an outpatient clinic treatment.
  • The patient agrees to comply with the protocol requirements, including the self care of wounds and all follow up visit requirements

Exclusion Criteria:

  • Pregnancy
  • Active or previous (within 8 weeks to the study screening visit) chemotherapy
  • Deep vein thrombosis within 6 months to the study screening visit
  • Lower extremity revascularization procedure (e. g. PTA, graft or other) within 8 weeks to the study screening visit
  • Current history of substance abuse
  • Physical or mental disability ( if not cared for, i. e. home nursing etc)or geographical concerns (residence not within reasonable travel distance to study center)that would hamper compliance with required study visits
  • Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 8 weeks to the study screening visit
  • The investigator believes that the subject will be unwilling or unable to comply with the study protocol requirements, including the ESWT procedure, standard of care self-care requirements and all study related follow-up visit requirements.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
ESWT 001 - 2003
Not Provided
Not Provided
Wolfgang SCHADEN, MD, UKH Meidling - AUVA
Not Provided
Principal Investigator: Klaus S. WOLFF, MD Heeresspital - Wien - Austrian Armed Forces Hospital - Vienna
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP